Posted by Michael Wonder on 27 Aug 2018
Update on proposal to fund a pangenotypic hepatitis C treatment - glecaprevir and pibrentasvir (Maviret)
27 August 2018 - PHARMAC would like to thank everyone who provided feedback on a proposal to fund glecaprevir and pibrentasvir (Maviret) for hepatitis C.
This was the subject of a consultation letter dated 20 July 2018, with a closing date for feedback of 13 August 2018.
After having reviewed the feedback, we have determined that we require additional time to consider the issues raised before a decision can be made on the proposal.
